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Cyclosporine A induced arteriolopathy in a rat model of chronic
cyclosporine nephropathy. Chronic cyclosporine (CsA) nephrotoxicity is a
major complication of heart, bone marrow, and renal transplantation, and
is characterized in humans by striped interstitial fibrosis, tubular dilatation
and atrophy, and hyalinization of hilar arterioles. This last feature is highly
specific for cyclosporine injuiy and has been difficult to reproduce in
normotensive animal models. Salt-depletion has been shown to sensitize
rodents to the effects of CsA and accelerate the disease process. We
conducted sequential studies in chronically salt depleted, pair fed rats
treated with CsA (15 mg/kg, s.c.) or an equivalent dose of olive oil vehicle,
and found a histologic lesion associated with CsA that consisted of striped
cortical interstitial fibrosis, tubular dilatation and atrophy, and hyaliniza-
tion of many afferent arterioles. The arteriolopathy was first detected at
day 10 with progressive hyalinization of arterioles continuing until termi-
nation of the study at day 35. The arteriolopathy consisted initially of
eosinophilic granular transformation of smooth muscle cells comprising
afferent hilar glomerular arterioles, and progressed to foci of smooth
muscle cell vacuolization and accumulation of discrete hyaline deposits in
vessel walls. Electron microscopy demonstrated marked accumulation of
typical renin granules throughout the smooth muscle cell cytoplasm,
corresponding to the eosinophilic granular transformation revealed histo-
logically. Immunocytochemistry confirmed the up-regulated production of
renin in these vessels. This study documents a rodent model for CsA
arteriolopathy and CsA-associated interstitial fibrosis that strikingly re-
produces the most characteristic nephropathic effects of cyclosporine
found in human patients treated with this agent. This model offers an
opportunity to test therapeutic interventions that might block or amelio-
rate the most serious nephrotoxic effects of this drug.
Cyclosporine (CsA) has improved organ transplantation sur-
vival markedly since its introduction by Borel et al [1], and
cyclosporine-based immunosuppression has been used success-
fully as therapy for a number of primary renal and non-renal
disease states as well. A major complication of long-term therapy
is chronic CsA nephropathy, characterized by tubular vacuoliza-
tion, striped cortical interstitial fibrosis, and a prominent vascular
injury manifested by hyalinosis of hilar arterioles, and terminal
portions of small muscular (interlobular) arteries [2]. This arte-
riolopathy is thought to be the most pathognomonic lesion of
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chronic CsA nephropathy. This renal arteriolopathy has been
documented in all solid organ transplant settings, involving the
native kidneys of recipients of heart [3—6] and liver allografts [7],
as well as transplanted kidneys [8—10]. It has also been docu-
mented in the kidneys of patients receiving bone marrow trans-
plants [6], and in those of patients being treated with CsA for
autoimmune diseases [11—15]. The lesion consists primarily of
endothelial cell swelling, and nodular hyaline protein deposition
in afferent arterioles associated with areas of smooth muscle cell
(SMC) injury and necrosis [16]. However, little is known about its
pathogenesis primarily due to the lack of an adequate animal
model.
This lesion has been reproduced in the SHR hypertensive rat
given super therapeutic doses of CsA [17], and some features of
this lesion have also been observed by electron microscopy in
Wistar rats given extremely high doses of CsA [18]. The arteriol-
opathy has also been described in rabbits receiving CsA [19].
However, a histologically distinguishable lesion resembling the
CsA arteriolopathy identified in sections of human renal biopsies
has not been identified to date in cyclosporine-treated normoten-
sive rats.
Salt depletion has been shown to increase the susceptibility of
rodents to the effects of CsA, and this maneuver facilitates
production of interstitial fibrosis that mimics the striped intersti-
tial fibrosis found in humans [20, 21]. In studies reported else-
where we have provided data on interstitial cellular events as they
relate to the subsequent development of fibrosis in this model [22,
23]. Here we document a model of chronic CsA nephropathy in
salt depleted rats in which a prominent component is the devel-
opment of an arteriolopathy that is virtually indistinguishable
morphologically from the CsA arteriolopathy in humans.
Methods
Experimental design
Forty-eight adult, male Sprague-Dawley rats (Charles River,
Wilmington, MA, USA), 225 to 250 g, were housed in individual
cages and fed a low sodium diet (0.05% sodium, Teklad, Premier,
WI, USA), with water ad libitum. After one week on a low salt
diet, weight matched rats were randomly assigned to CsA admin-
istration of 15 mg/kg s.c. daily (Sandoz Research Inst., East
Hanover, NJ, USA), or an equivalent dose of the vehicle, olive oil.
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Fig. 1. A. Representative cortical structures from a control rat. Normal
appearance of glomeruli, tubules, interstitium and hilar arteriole (arrow)
is demonstrated. PAS stain, 365X. B. Day 10 cyclosporine treated animal.
Smooth muscle cells of an affected hilar arteriole (arrow) are hypertro-
phied and show granular eosinophilic transformation compared to normal
arteriole seen in 1A. PAS stain, 365 X. C. Day 10 cyclosporine-treated
animal. Cyclosporine effect on vascular smooth muscle cells is limited to
the terminal arteriole. The more proximal arterial smooth muscle cells are
morphologically normal. PAS stain, 365X.
Fig. 2. A. Day 35 cyclosporine-treated animal. There is discrete eosino-
philic transformation of some, but not all, smooth muscle cells comprising
a hilar arteriole (arrow). Adjacent glomerulus and tubular structures are
morphologically normal. PAS stain, 470x. B. Day 35 cyclosporine-treated
animal. More uniform, circumferential injuiy of hilar arteriolar smooth
muscle cells. PAS stain, 470X. C. Day 26 cyclosporine-treated animal.
There is focal smooth muscle cell injury of the glomerular afferent
arteriole (arrow), with sparing of contiguous terminal interlobular artery
(arrowhead) and sparing of efferent arteriole (double arrow). PAS stain,
470x.
Rats were pair fed and control and CsA treated rats were each Histology
further divided into four groups of six rats each. Control and Renal tissue at sacrifice was fixed in methyl Carnoy's solution,
experimental groups were sacrificed and renal tissue was obtained processed and embedded in paraffin, and cut into 4 a sections
at days 5, 10, 26, and 35. using conventional techniques. Slides were stained with periodic
Fig. 3. Evidence ofpathologic involvement of terminal arterial and arteriolar
smooth muscle cells, with sparing of more proximal arterial cells, in three different
mtc treated for 26 days (A, B) and 35 days (C, U) with cyclosporine. A. Distinct
deposits of eosinophulic hyaline material are found between smooth muscle
cells of the terminal portion of an interlobular arteiy (arrow). Other arterial
segments (a) are normal. PM stain, 320X. B. Magnification of lesion in A.
Nodular, granular hyaline deposits are present in media and adventitial
portions of vessel wail, with sparing of endothelium and intima from injuty.
PM stain, 520x. C. Arteriolar but not adjacent smooth muscle cells are
injured. PAS stain, 420X. D. Focal, discrete nodular hyaline deposits in media
and adventitial locations of vessel wall, virtually indistinguishable in appear-
ance from human cyclosporine arteriolopathy. PAS stain, 42tlX. E. For
comparison with U, an example of human cyclosporine-associated arteriol-
opathy in a renal allograft in which measurements of renal dysfunction
improved solely with reduction of the cyclosporine dosage unaccompanied by
increases in other immunosuppressive therapy. PAS stain, 165X.
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acid and Schiff's reagent (PAS), with a hematoxylin counterstain.
Tissue sections were assessed for morphologic changes. Immuno-
histochemical staining of the sections was performed utilizing a
murine monoclonal antibody raised against human renin as
previously described [24, 251, using standard immunoperoxidase
procedures [26]. Controls included substitution of the primaly
antibody with a irrelevant monoclonal antibody.
Electron microscopy
Portions of the renal tissue specimens were fixed in 1/2 strength
Karnovsky's solution and processed as previously described [26].
Thin sections were mounted on coated nickel grids, and stained
with osmium followed by uranyl acetate. Sections were examined
using a Phillips 410 electron microscope.
Results
Renal functional data for the animals reported in this investi-
gation are given in the companion manuscript to this study [23].
Of specific note, no differences in blood pressure between cyclo-
sporine treated and control rats were identified at any time point
studied. CsA treated animals developed a recognizable and
widespread afferent arteriolar hyalinosis by day 10, with the most
advanced lesions observed at days 26 and 35. The hyalinization
was confined to the afferent arterioles and spared contiguous
more proximal portions of the arterial tree, comprising interlob-
ular and larger arteries. In many examples, the arterial tree could
be followed from the interlobular arteries to the terminal afferent
arterioles of individual glomeruli. Such examples permitted the
demonstration that it was the afferent arteriole and not the more
proximal contiguous arterial structures, nor adjacent efferent
arterioles unattached to larger arteries, that were affected by the
hyalinosis lesions (Figs. 1 to 3). The normal rat glomerular hilar
arteriole is composed of a thin single layer of smooth muscle cells
overlying an endothelial lining (Fig. 1A). In salt depleted animals
after 10 days of cyclosporine treatment, approximately 1/5 to 1/2
of all identifiable arterioles showed swelling of some or all of the
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Fig. 4. A. Normal pattern of rat arteriolar and juxtaglomenilar apparatus
expression of renin as detected immunocytochemically. Immunoperoxidase,
300X. B. Day 35 cyclosporine-treated animal. There is more widespread
renin expression by the hilar arterial and arteriolar vasculature as well as
other components of the juxtaglomerular apparatus. Immunoperoxidase,
175 x.
smooth muscle cells present in the histologic associated plane of
section, with diffuse eosinophilic granular transformation of the
cell cytoplasm (Fig. 1 B, C). No evidence of glomerular injury,
endothelial cell damage, or extracellular matrix deposition was
detectable at this time point, although there was mild cortical
tubular dilatation.
By days 26 and 35 after initiation of cyclosporine treatment, the
arteriolar changes were more widespread, involving the majority
of all identifiable arterioles. In affected vessels, the lesions more
often, although not uniformly, involved all of the smooth muscle
cells rather than just single cells, resulting in a circumferential
appearance of the lesion (Fig. 2). As affected smooth muscle cells
became hypertrophied, the distinct granular character of the
eosinophilic transformation at times became obscured. Occasion-
ally, the hyaline proteinaceous deposits encountered in day 26 and
day 35 specimens were localized between viable smooth muscle
cells of the vessel media, as well as occurring as discrete nodules
at the adventitial surface of the vessel media (Fig. 3). This was
indistinguishable from the pattern of cyclosporine arteriolopathy
as it occurs in humans (Fig. 3E). These lesions were also
associated with focal vacuolization of vessel smooth muscle cells.
In no case were subendothelial hyaline accumulations identified
as a principal manifestation of arteriolopathy, and in no case was
there evidence of inflammatory cell infiltration of vessel walls.
In normal animals, immunohistochemical stains for renin
Fig. 5. Ultrastructural appearance of hilar arteriole entering glomerulus (g)
with diffuse accumulation of membrane-bound renin granules (r) in arteriolar
smooth muscle cells. 2400X.
showed prominent circumferential expression of renin by all the
SMC comprising the glomerular hilar arterioles, without evidence
of expression within more proximal muscular arteries (Fig. 4A).
Immunohistochemical detection of renin in CsA treated animals
showed both enhanced staining of the juxtaglomerular (JG)
apparatus, as well as staining of glomerular hilar arterioles that
was often similar to that seen in control animals. However, in day
35 rats, there was focal accentuation of arteriolar staining in areas
appearing to correspond to hyaline deposition (Fig. 4B). This
could not be reliably ascertained due to the obscuring of under-
lying vessel architectural detail by the intense staining observed
with the renin antibody. Most significantly, in day 35 CsA treated
animals, there was proximal extension of normal arteriolar stain-
ing for renin, including distal portions of interlobular arteries in
some vessels. However, this was not a uniform finding within the
CsA group.
Electron microscopy of day 35 CsA treated animals demon-
strated focal but dramatic changes in arterioles compared to
controls. Smooth muscle cells of arterioles demonstrating focal or
diffuse hyaline transformation, as detected by histologic examina-
tion of screening plastic sections, were found to contain diffuse
cytoplasmic accumulations of membrane bound granules with a
morphologic appearance characteristic of renin granules. In some
arterioles there was diffuse transformation of all the smooth
muscle cells comprising the vessel wall by this process (Fig. 5); in
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Fig. 6. A. Arteriole showing discrete involvement of some, but not all smooth muscle cells by a process of cell swelling and cytoplasmic accumulation of
granules similar to those of Figure 5. 2270X. B. Higher magnification of vessel in A, also demonstrating cytoplasmic granules, and the absence of
morphologic injmy to endothelium. 4800x.
others the process involved only a subset of vascular smooth
muscle cells (Fig. 6). These studies confirmed the discreteness of
the injury to specific smooth muscle cells. Cells showing diffuse
cytoplasmic transformation could be found adjacent to smooth
muscle cells without any evidence of such injury. No ultrastruc-
tural abnormalities were discerned in glomeruli or arterial struc-
tures adjacent to affected arterioles. There appeared to be a
morphologic transition between smooth muscle cells showing
diffuse cytoplasmic accumulations of granules to cells showing
lesser numbers of such granules dispersed in a finely granular,
amorphous electron dense material similar to hyaline material
ascribed to cellular and proteinaceous debris in the setting of
human vascular injury (Fig. 7). No examples of hyaline-like
deposits without some persistence of intracytoplasmic granules
were detected within the time frame of this study.
Discussion
In humans, a number of systemic disease processes can result in
arteriolar hyalinosis. These include hypertension, aging and dia-
betes. The microvascular manifestations occurring as a result of
each of these injuries demonstrate considerable morphologic
overlap, and are often indistinguishable. All are characterized by
predominantly subendothelial collections of nondescript hyaline
material, a material thought to be composed of insudated plasma
proteins. CsA associated arteriolopathy (and perhaps FK 506
arteriolopathy as well) is distinguished from these other entities
by the characteristic localization of hyaline deposits within the
medial layers of smooth muscle cells and at the outer surface of
affected vessels [27—291. In this form of injury, subendothelial
hyaline is not a characteristic feature. CsA arteriolopathy in
humans also has a peculiar localization to afferent arterioles and
terminal portions of interlobular arteries [27, 29, 30}. A model of
cyclosporine arteriolopathy should replicate these morphologic
findings as closely as possible and should be free of confounding
physiologic parameters such as hypertension and hyperglycemia if
at all possible.
In this report we document a model of chronic CsA nephrop-
athy in normotensive rodents, with hyalinization of afferent
arterioles that is strikingly similar to CsA-induced human arte-
riolopathy. The arteriolopathy appears to be widespread and
progressive in the setting of continued CsA exposure. Perhaps
most importantly, some morphologic features of this model
closely resemble human CsA arteriolopathy by virtue of the
distinct involvement of the muscular wall of the afferent arterioles
as opposed to the nondescript, subendothelial accumulation of
hyaline material that is nonspecifically found in other human
arteriolopathies as noted above, and furthermore, by the distinct
anatomic localization to afferent arterioles and not the proximal
portions of the renal arterial tree.
However, it must also be recognized that there may be some
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Fig. 7. Afferent arteriole (a) entering glomendus (g). Arteriolar smooth muscle cells show diminished numbers of renin granules compared with vessels
in Figures 5 and 6, and show some degeneration of organelle structures and cytoplasmic accumulation of ill defined, at times granular, pale material
with some features of the hyaline material seen in human cyclosporine arteriolopathy. 2980X.
important differences between the rat model presented in this
paper and human cyclosporine arteriolopathy. The demonstration
of large accumulations of renin granules in the human lesion has
not been reported, perhaps because the lesions identified in
humans are typically well established and likely to represent a late
stage in the morphological evolution of this injury. At such a
juncture, there is extensive degenerative change within the injured
smooth muscle cells, obscuring the features characteristic of
developing injury as we have studied it in the rat. Furthermore,
there is a potential discrepancy in relating cycloporine arteriol-
opathy to increased arteriolar renin production in that plasma
renin activity in humans treated with cyclosporine, unlike rats, is
typically unchanged or even depressed compared to untreated
controls [36]. However, this discrepancy may be more theoretical
than real, since multiple intervening steps subsequent to renin
synthesis and packaging in granules, which are not well charac-
terized, but which include those regulating local renin secretion
and activation, could have major effects on measured levels of
renin activity.
Salt depletion appears to be a critical factor in the development
of CsA arteriolopathy in the rat, as it is in other manifestations of
experimental cyclosporine induced nephropathy [20, 21, 31]. This
conclusion is based upon the observation that the arteriolopathy
has not been identified to date in non-salt depleted models of
experimental cyclosporine injury in the rat. Salt depletion was
originally employed to accentuate the "tubular glomerular feed-
back" loop [32] that contributes to increased renal vascular
resistance via the renin-angiotensin system (RAS), which is based
on the amount of chloride delivered to the macula densa of the
distal tubule. The ensuing hypothesis predicts that salt-depletion
would accelerate CsA induced disease in animals at least in part
as a function of the resistance changes. Our study, in conjunction
with the efforts of others who have not utilized salt depleted
models, and who have not encountered noteworthy arteriolopa-
thy, indicates CsA arteriolopathy also is accentuated in the
salt-depleted rat model. This in turn implicates the renin-angio-
tensin system in the pathogenesis of this lesion, although other
factors such as enhanced endothelin production or activity have
clearly been implicated in this disease [33—35]. The morphologic
correlation of smooth muscle "hyaline" injury and intracellular
accumulation of renin granules detected by electron microscopy
further identifies alterations in the intrarenal arteriolar renin
system as an important component in the development of arte-
riolopathy. Finally, enhanced arteriolar accumulation of renin was
detected immunocytochemically, a finding made by others as well
[36], which also points to a role for local stimulation of renin
production in the development of cyclosporine arteriolopathy.
With the model presented in this study, the hypothesis that
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enhanced renin production and/or activity is essential to the
development of CsA arteriolopathy can be tested. For example,
blockade of the RAS with the angiotensin-Il receptor antagonist,
Losartan [37], and the angiotensin converting enzyme-inhibitor,
enalapril [38], reported to reduce interstitial fibrosis, can be
examined as to whether or not they decrease the formation of the
arteriolopathy. Another test of validity of this model would be a
more extended observational study to characterize the evolution
of the arteriolar hyaline lesion into a more amorphous accumu-
lation of granular hyaline material that is suggested by the findings
in some day 35 experimental animals, and that is characteristic of
established human CsA arteriolopathy. A final approach would be
immunohistochemical studies of human CsA arteriolopathy in its
various morphologic stages that might identify renin accumulation
early in the development of this lesion. Each of these studies is
currently under way.
CsA arteriolopathy was at first thought to be an irreversible
lesion, but now has shown to be reversible with stopping or
lowering the dose of the drug [29, 30]. If validated, this model will
allow a means to define therapeutic interventions that can con-
tribute to amelioration of this form of injury.
In summary, the salt-depleted model of chronic cyclosporine
nephropathy produces alterations of afferent arterioles which are
similar to the lesion produced by CsA in humans. We conclude
that this is a relevant model that may be used to study the
long-term effects of cyclosporine nephrotoxicity.
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